DiaMedica Reports Q1 2026 Earnings and Clinical Trial Updates
DiaMedica (DMAC) reported a cash balance of $51.3 million as of March 31, 2026, sufficient to fund operations through 2027. The company used $9.1 million in net cash from operating activities during the quarter and increased R&D expenses due to clinical trial expansion.
Tickers: $DMAC